This GI-restricted inhibitor of TGFβR1 (ALK5) is specifically engineered to target TGFβ signalling, an essential regulator of fibrosis, with the goal of decreasing the necessity for bowel resection surgery in individuals with fibro-stenotic Crohn’s disease [55]. This evidence concerns the gene TGFBR1 and Crohn disease.